Wolff Financial Management LLC Trims Holdings in Eli Lilly and Company $LLY

Key Points

• Wolff Financial Management LLC has reduced its position in Eli Lilly and Company by 4.6%, now holding 8,403 shares valued at $6.55 million, making it the 11th largest holding in their portfolio.
• Eli Lilly recently reported earnings of $6.31 per share, surpassing analyst estimates, with revenues reaching $15.56 billion, a 37.6% increase year-over-year.
• Institutional investors and hedge funds collectively own 82.53% of Eli Lilly's stock, indicating strong institutional confidence in the company.

Wolff Financial Management LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,403 shares of the company's stock after selling 402 shares during the period. Eli Lilly and Company accounts for about 1.7% of Wolff Financial Management LLC's holdings, making the stock its 11th biggest position. Wolff Financial Management LLC's holdings in Eli Lilly and Company were worth $6,550,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LLY. WestEnd Advisors LLC grew its stake in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $27,000. Citizens National Bank Trust Department grew its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $40,000. Finally, Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $43,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 1.2%

NYSE:LLY traded down $9.41 during midday trading on Friday, reaching $753.52. 7,319,147 shares of the stock traded hands, compared to its average volume of 3,181,974. The company has a fifty day moving average of $738.37 and a 200 day moving average of $771.89. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.86. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market capitalization of $713.18 billion, a P/E ratio of 49.25, a PEG ratio of 1.06 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the business posted $3.92 EPS. The firm's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company's payout ratio is presently 39.22%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. cut their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday. Cantor Fitzgerald cut their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Finally, Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $939.61.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.